Key clinical point: Intrathecal prophylaxis appears ineffective at preventing central nervous system (CNS) relapse in diffuse large B-cell lymphoma (DLBCL) patients receiving anthracycline-based immunochemotherapy.
Major finding: The cumulative incidence of CNS relapse ranged from 1.9% to 8.4%, and intrathecal prophylaxis was not associated with a significant reduction in the risk of CNS relapse in any study.
Study details: A systematic review of 14 studies encompassing 7,357 DLBCL patients who received regimens containing rituximab or obinutuzumab.
Disclosures: Two authors reported honoraria from Roche Pharmaceuticals.
Eyre TA et al. Haematologica. 2019 Sep. doi:10.3324/haematol.2019.229948.